Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented data on Actimab-A, an antibody radiation conjugate, at the 36th Annual Meeting of the Society for Immunotherapy for Cancer from November 12-14, 2021. The findings demonstrated that Actimab-A, when combined with a CD47 blocking antibody, significantly increased survival in AML tumor models and enhanced cell surface calreticulin levels, potentially improving the immune response. This combination indicates promising therapeutic potential for treating acute myeloid leukemia (AML).

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced the completion of patient enrollment in its Phase 1 trial of Actimab-A combined with CLAG-M chemotherapy for relapsed or refractory acute myeloid leukemia (AML) patients. The final cohort received 1.0 μCi/kg of Actimab-A. Previous cohorts showed a 100% remission rate at a lower dose. Data will be presented at the American Society of Hematology meeting in December, and the company anticipates updates on future developments by year-end.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced that multiple abstracts showcasing its Iomab-B and Actimab-A clinical programs are set for presentation at the 63rd American Society of Hematology Annual Meeting in Atlanta, GA, from December 11-14, 2021. Notably, the pivotal Phase 3 SIERRA trial for Iomab-B has completed patient enrollment, with interim data to be presented at ASH. The company aims to demonstrate the efficacy of its targeted therapies in improving outcomes for patients with unmet medical needs, particularly in AML treatments.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced that two abstracts on targeted radiotherapies combined with CD47 antibody immunotherapy will be presented at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) from November 12-14, 2021. The titles focus on enhancing anti-tumor effects in solid tumors and acute myeloid leukemia. CEO Sandesh Seth expressed excitement about the R&D advancements and the company's efforts in the immunotherapy field. Full posters will be available on Actinium's website on November 9, 2021.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27 to 30, 2021. The company's presentation is scheduled for September 29 at 3:20 p.m. ET. Attendees can access the webcast via Actinium's investor relations website. Actinium focuses on developing targeted radiotherapies, particularly Antibody Radiation-Conjugates, aimed at improving treatment outcomes for cancer patients with high unmet needs. The company's lead candidate is I-131 apamistamab (Iomab-B), being studied in pivotal trials.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced several key senior leadership appointments aimed at advancing its growth strategy. Arun Swaminathan, Ph.D., has been appointed as Chief Business and Commercial Officer, while Paul Diamond, Ph.D., joins as Vice President, Patent and Legal Counsel. Avinash Desai, M.D., has been promoted to Chief Medical Officer. These leaders together bring over 50 years of experience in biopharmaceuticals, enhancing Actinium's focus on its pipeline, particularly the recently completed Phase 3 SIERRA trial for Iomab-B.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced its participation in four upcoming investor conferences, highlighting its pivotal Phase 3 trial for Iomab-B and upcoming milestones from its targeted radiotherapy pipeline. The conferences are scheduled from September 27 to October 13, 2021. CEO Sandesh Seth emphasized the strong momentum as the company approaches significant data updates in the fourth quarter. Actinium specializes in targeted radiotherapies aimed at treating patients with unmet needs, focusing on improving outcomes through innovative therapies.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has completed enrollment in the pivotal Phase 3 SIERRA trial for Iomab-B, aimed at treating patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial, involving 150 patients across 24 centers in the U.S. and Canada, assesses the efficacy of Iomab-B in providing Bone Marrow Transplant (BMT) access. Actinium plans to present data updates in Q4 2021 and topline results in mid-2022 to support a Biologics License Application (BLA) for Iomab-B.